More Stelara Rivals Hit US, With Discounts Already Reaching 90%

Teva, Sandoz And Biocon Biologics Confirm Ustekinumab Biosimilar Launches

 
• By Dave Wallace
  
US price competition is expected to be severe on ustekinumab (Shutterstock)

More from Biosimilars

More from Business